HHS Secretary Becerra Claims COVID Vaccines ‘Kill People Of Color’ At ‘Twice The Rate Of Whites,’ Vows To ‘Work’ Harder To Get More People Vaccinated

Authors: Alicia Powe Published April 19, 2022

After months of mandates forcing people to get two and three doses of COVID-19 vaccines to keep their jobs attend, school, travel and enter indoor venues, the federal government admits the experimental gene modification shots are killing people.

While vowing to ramp up biomedical tyranny and the effort to get more Americans vaccinated, U.S. Health and Human Services Director Xavier Becerra Experimental claimed the “safe and effective” mRNA shots are killing people with dark skin at a much higher rate than those with light skin.

“By the way, we know that vaccines are killing people of color — blacks, Latinos, indigenous people — at about two times the rate of white Americans,” Becerra explained during a digital “White House Convening on Equity” seminar on April 14.

After months of mandates forcing people to get two and three doses of COVID-19 vaccines to keep their jobs attend, school, travel and enter indoor venues, the federal government admits the experimental gene modification shots are killing people.

While vowing to ramp up biomedical tyranny and the effort to get more Americans vaccinated, U.S. Health and Human Services Director Xavier Becerra Experimental claimed the “safe and effective” mRNA shots are killing people with dark skin at a much higher rate than those with light skin.

“By the way, we know that vaccines are killing people of color — blacks, Latinos, indigenous people — at about two times the rate of white Americans,” Becerra explained during a digital “White House Convening on Equity” seminar on April 14.

After acknowledging the lethality of COVID shots, Becerra explained that approximately 80 percent of the American public is vaccinated.

But the government needs to “work” harder to vaccinate Americans who have refrained from getting inoculated, he argued.

“So, on vaccines, last year, we saw that about two-thirds of white American adults had received at least one shot of vaccine,” Becerra said. “That was just barely over 50 percent for black Americans and Latinos at that particular time. So, again, we’ve got to work.

“Today, a year later, over 80 percent of white American adults have received at least one shot. Over 80% of black American adults have received at least one shot. Over 80 percent of Latino Americans have received at least one vaccine shot.”

While HHS acknowledges the deadly effects COVID vaccines have on minority communities, the Center for Disease Control and Prevention’s Vaccine Adverse Effects System confirms the COVID shots are killing more people than any other vaccine in history.

According to VAERS, only 421 vaccine-related deaths in 2020 prior to the administration of the mRNA shots. In 2021, the number of people who dies after getting vaccinated precipitously spiked with at least 21,914 people died after receiving the COVID shots.

As yet, 5689 people died after receiving a COVID vaccine in 2022.

Meanwhile, the CDC is deploying fleets of federally funded “pandemic” buses to minority communities across the nation to persuade unvaccinated Americans into getting jabbed.

As reported, the CDC’s PANDEMIC (Program to Alleviate National Disparities in Ethnic and Minority Immunizations in the Community) deploys teams of health care workers into minority communities to educate people about why they need to be vaccinated.

According to PANDEMIC grant program materials, PANDEMIC’s goal is to reach groups that may experience “immunization disparities” in racial and ethnic minorities, residents of rural communities, migrant farmworkers, Native Americans, Hispanics, Blacks, and people identifying as part of the LGBTQ community and boost vaccination rates in areas chosen for having “high vaccine-hesitancy rate. ”

“If people aren’t sure [that they want the vaccine], then we have educational materials, and our community health workers and the extension agents will talk to them about their particular questions and try to answer their questions and their concerns. And then…[we] immediately give them the vaccine,” explained Catherine Striley of the University of Florida, who helps oversee the PANDEMIC project.

COVID-19 vaccine surveillance report Week 3

Latest UK Data Shows Covid Infection RATE Among the Triple Jabbed (Boosted) Is HIGHER And RISING FASTER Than The Unvaccinated Across ALMOST EVERY Age Group

20 January 2022

Executive summary
Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous
clinical trials have been undertaken to understand the immune response, safety profile and
efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines
as they are rolled out in the population is important to continually ensure that clinical and public health guidance on the vaccination program is built upon the best available evidence. UK Health Security Agency (UKHSA), formerly Public Health England (PHE), works closely with the Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and other government, devolved administration and academic partners to monitor the COVID-19 vaccination program. Details of the vaccine surveillance strategy are set on the page COVID-19: vaccine surveillance strategy (1). As with all vaccines, the safety of COVID-19 vaccines is continuously being monitored by the MHRA. They conclude that overall, the benefits of COVID-19 vaccines outweigh any potential risks (2).

Vaccine effectiveness

Several studies of vaccine effectiveness have been conducted in the UK against different
COVID-19 variants. Vaccine effectiveness against symptomatic disease with the Omicron
variant is substantially lower than against the Delta variant, with rapid waning. However,
protection against hospitalisation remains high, particularly after 3 doses.

Population impact

The impact of the vaccination program on the population is assessed by taking into account
vaccine coverage, evidence on vaccine effectiveness and the latest COVID-19 disease surveillance indicators. Vaccine coverage tells us about the proportion of the population that have received 1, 2 and 3 doses of COVID-19 vaccines. By 16 January 2022, the overall vaccine uptake in England for dose 1 was 68.9% and for dose 2 was 63.6%. Overall vaccine uptake in England in people with at least 3 doses was 48.4%. In line with the program rollout, coverage is highest in the oldest age groups.

We present data on COVID-19 cases, hospitalizations and deaths by vaccination status. These
raw data should not be used to estimate vaccine effectiveness as the data does not take into account inherent biases present such as differences in risk, behavior and testing in the
vaccinated and unvaccinated populations. Vaccine effectiveness is measured in other ways as
detailed in the ‘Vaccine Effectiveness’ section. Based on antibody testing of blood donors, 98.7% of the adult population now have antibodies to COVID-19 from either infection or vaccination compared to 24.1% that have antibodies from infection alone.

COVID-19 vaccine surveillance report – week 3- 4

Vaccine effectiveness

Large clinical trials have been undertaken for each of the COVID-19 vaccines approved in the
UK which found that they are highly efficacious at preventing symptomatic disease in the
populations that were studied. The clinical trials have been designed to be able to assess the
efficacy of the vaccine against laboratory confirmed symptomatic disease with a relatively short follow up period so that effective vaccines can be introduced as rapidly as possible. Post implementation real world vaccine effectiveness studies are needed to understand vaccine effectiveness against different outcomes (such as severe disease and onwards transmission), effectiveness in different subgroups of the population and against different variants as well as to understand the duration of protection. Vaccine effectiveness is estimated by comparing rates of disease in vaccinated individuals to rates in unvaccinated individuals.

Below we outline the latest real-world evidence on vaccine effectiveness from studies in UK
populations. Where available we focus on data related to the Omicron variant which is currently dominant in the UK. The findings are also summarized in Table 2.

Effectiveness against symptomatic disease

Vaccine effectiveness against symptomatic COVID-19 has been assessed in England based on
community testing data linked to vaccination data from the National Immunisation Management
System (NIMS), cohort studies such as the COVID Infection Survey and GP electronic health
record data. After 2 doses of AstraZeneca vaccine, vaccine effectiveness against the Omicron
variant starts at 45 to 50% then drops to almost no effect from 20 weeks after the second dose.
With 2 doses of Pfizer or Moderna effectiveness dropped from around 65 to 70% down to
around 10% by 20 weeks after the 2nd dose. 2 to 4 weeks after a booster dose of either the
Pfizer or Moderna vaccine, effectiveness ranges from around 65 to 75%, dropping to 55 to 65%
at 5 to 9 weeks and 45 to 50% from 10+ weeks after the booster. Vaccine effectiveness
estimates for the booster dose are very similar, irrespective of the primary course received (3).
Vaccine effectiveness is generally slightly higher in younger compared to older age groups.

SEE FULL REPORT by selecting link below:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1049160/Vaccine-surveillance-report-week-3-2022.pdf

Study Finds Teenage Boys Six Times More Likely To Suffer Heart Problems From Vaccine Than Be Hospitalized by COVID

Authors; Paul Joseph Watson via Summit News,

Research conducted by the University of California has found that teenage boys are six times more likely to suffer from heart problems caused by the COVID-19 vaccine than to be hospitalized as a result of COVID-19 itself.

“A team led by Dr Tracy Hoeg at the University of California investigated the rate of cardiac myocarditis – heart inflammation – and chest pain in children aged 12-17 following their second dose of the vaccine,” reports the Telegraph.

“They then compared this with the likelihood of children needing hospital treatment owing to Covid-19, at times of low, moderate and high rates of hospitalisation.”

Researchers found that the risk of heart complications for boys aged 12-15 following the vaccine was 162.2 per million, which was the highest out of all the groups they looked at.

This compares to the risk of a healthy boy being hospitalized as a result of a COVID infection, which is around 26.7 per million, meaning the risk they face from the vaccine is 6.1 times higher.

Even during high risk rates of COVID, such as in January this year, the threat posed by the vaccine is 4.3 times higher, while during low risk rates, the risk of teenage boys suffering a “cardiac adverse event” from the vaccine is a whopping 22.8 times higher.

The research data was based on a study of adverse reactions suffered by teens between January and June this year.

In a sane world, such data should represent the nail in the coffin for the argument that teenagers and children should be mandated to take the coronavirus vaccine, but it obviously won’t.

In the UK, the government is pushing to vaccinate 12-15-year-olds, even without parental consent, despite the Joint Committee on Vaccination and Immunisation (JCVI) advising against it.

Meanwhile, in America, Los Angeles County school officials voted unanimously to mandate COVID shots for all

First case of postmortem study in a patient vaccinated against SARS-CoV-2

Author:TorstenHansenaUlfTitzeaNidhi Su AnnKulamadayil-HeidenreichbSabineGlombitzacJohannes, et. al.

Highlights

• We report on a patient with a single dose of vaccine against SARS-CoV-2.

• He developed relevant serum titer levels but died 4 weeks later.

• By postmortem molecular mapping, we found viral RNA in nearly all organs examined.

• However, we did not observe any characteristic morphological features of COVID-19.

Immunogenicity might be elicited, while sterile immunity was not established.

Abstract

A previously symptomless 86-year-old man received the first dose of the BNT162b2 mRNA COVID-19 vaccine. He died 4 weeks later from acute renal and respiratory failure. Although he did not present with any COVID-19-specific symptoms, he tested positive for SARS-CoV-2 before he died. Spike protein (S1) antigen-binding showed significant levels for immunoglobulin (Ig) G, while nucleocapsid IgG/IgM was not elicited. Acute bronchopneumonia and tubular failure were assigned as the cause of death at autopsy; however, we did not observe any characteristic morphological features of COVID-19. Postmortem molecular mapping by real-time polymerase chain reaction revealed relevant SARS-CoV-2 cycle threshold values in all organs examined (oropharynx, olfactory mucosa, trachea, lungs, heart, kidney and cerebrum) except for the liver and olfactory bulb. These results might suggest that the first vaccination induces immunogenicity but not sterile immunity.

Keywords

SARS-CoV-2VaccineAutopsyHistologyRT-PCR

We report on an 86-year-old male resident of a retirement home who received vaccine against SARS-CoV-2. Past medical history included systemic arterial hypertensionchronic venous insufficiencydementia and prostate carcinoma. On January 9, 2021, the man received lipid nanoparticle-formulated, nucleoside-modified RNA vaccine BNT162b2 in a 30 μg dose. On that day and in the following 2 weeks, he presented with no clinical symptoms (Table 1). On day 18, he was admitted to hospital for worsening diarrhea. Since he did not present with any clinical signs of COVID-19, isolation in a specific setting did not occur. Laboratory testing revealed hypochromic anemia and increased creatinine serum levels. Antigen test and polymerase chain reaction (PCR) for SARS-CoV-2 were negative.

For More Information: https://www.sciencedirect.com/science/article/pii/S1201971221003647

Japan probes two deaths after jabs from tainted Moderna batch

Sat, August 28, 2021, 6:10 AM

Japan is investigating the death of two men who received jabs from batches of Moderna’s Covid-19 vaccine suspended from use due to contamination, the health ministry said Saturday.

The men aged 30 and 38 died earlier this month after getting their second Moderna doses from one of three manufacturing lots suspended by the government on Thursday after several vials were found to be contaminated, the ministry said in a statement.

The ministry said the cause of death was still being investigated and “currently, causal relations with the vaccinations are unknown”.- ADVERTISEMENT –

Both men contracted fever after receiving their vaccinations and neither had underlying health conditions or allergic history, the ministry said.

The suspension affects 1.63 million doses of Moderna Covid vaccines, which have been reportedly shipped to over 800 vaccination centres across Japan.

Takeda, which is in charge of sales and distribution of the Moderna shot in Japan, said it received reports from several vaccination centres that “foreign substances” have been found inside unopened vials.

Around 44 percent of Japan’s population has been fully vaccinated, as the country battles a record surge of virus cases driven by the more contagious Delta variant.

Over 15,700 people have died from Covid-19 in the country, and large parts of Japan are under strict virus restrictions.